Angiotensin II Stimulates Matrix Metalloproteinase Secretion in Human Vascular Smooth Muscle Cells via Nuclear Factor-κB and Activator Protein 1 in a Redox-Sensitive Manner
- 28 September 2005
- journal article
- Published by S. Karger AG in Journal of Vascular Research
- Vol. 42 (5), 415-423
- https://doi.org/10.1159/000087451
Abstract
The renin-angiotensin system contributes to atherogenesis. Matrix metalloproteinases (MMP) are thought to participate in plaque destabilization through degradation of extracellular matrix. This study tested whether angiotensin II (ANG II) induces MMP in human vascular smooth muscle cells (SMC). ANG II induced expression of MMP-1, -3, and -9, but not of MMP-2 in SMC. The expression of MMP-1, a key enzyme for collagen degradation, was studied in detail. SMC stimulated with ANG II concentration-dependently released enzymatically active MMP-1. The ANG II type 1 receptor antagonists losartan and candesartan blocked ANG-II-induced MMP-1 release. Inhibition experiments with actinomycin D suggest ANG-II-induced MMP-1 mRNA regulation at the transcriptional level. Decoy oligodeoxynucleotides against nuclear factor-kappaB and activator protein 1 inhibited MMP-1 secretion, demonstrating participation of these transcription factors in MMP-1 transcription. Stimulation of MMP-1 by ANG II depended on cyclooxygenase 2. The antioxidants pyrrolidine dithiocarbamate and N-acetylcysteine, the flavin protein inhibitor diphenylene iodonium, and the NADP(H) oxidase inhibitor apocynin blocked MMP-1 release, suggesting a redox-sensitive mechanism involving NADP(H) oxidase. The reactive oxygen species (ROS) donor 2,3-dimethoxy-1,4-naphthoquinone induced MMP-1 secretion and enhanced ANG-II-stimulated MMP-1 expression. These findings indicate that ROS may increase their own production by activation of NADP(H) oxidase. The capability of ANG II to induce functionally active MMP in human SMC may contribute to the altered plaque composition seen in complicated stages of atherosclerosis.Keywords
This publication has 41 references indexed in Scilit:
- A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimersBiochemical Journal, 2003
- Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-κB by Losartan in Hypercholesterolemic RabbitsJournal of Cardiovascular Pharmacology, 2002
- Effect of Ramipril and Furosemide Treatment on Interstitial Remodeling in Post-Infarction Heart Failure Rat HeartsJournal of Molecular and Cellular Cardiology, 2002
- Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cellsCardiovascular Research, 2001
- The terminal complement complex C5b‐9 stimulates interleukin‐6 production in human smooth‐muscle cells through activation of transcription factors NF‐κB and AP‐1The FASEB Journal, 2000
- Angiotensin II Activates the Proinflammatory Transcription Factor Nuclear Factor-κB in Human MonocytesBiochemical and Biophysical Research Communications, 1999
- Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.Journal of Clinical Investigation, 1996
- Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnoverThe American Journal of Cardiology, 1995
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994
- Activation of human peripheral monocytes by angiotensin IIFEBS Letters, 1994